Fed Circuit affirms generic maker’s win over Eagle

11-05-2020

Sarah Morgan

Fed Circuit affirms generic maker’s win over Eagle

Bill Perry / Shutterstock.com

The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo (bendamustine hydrochloride injection).


US Court of Appeals for the Federal Circuit, generics, Eagle Pharmaceuticals, Belrapzo, Slayback Pharma, patent infringement,

LSIPR